Latest Breaking News On - Tarsus pharmaceuticals daily - Page 5 : comparemela.com

Tarsus Pharmaceuticals (TARS) Outperform Rating Reaffirmed at Lifesci Capital

Tarsus Pharmaceuticals (TARS) Outperform Rating Reaffirmed at Lifesci Capital
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Josem trevejoBobakr azamianTarsus pharmaceuticals incNews ratings for tarsus pharmaceuticals dailyArtisan partners limited partnershipInstitutional investors weigh in on tarsus pharmaceuticalsTarsus pharmaceuticals company profileGoldman sachs groupBlackrock incTarsus pharmaceuticalsDeerfield management companylp seriesTarsus pharmaceuticals stock performanceLifesci capitalFree reportModerate buyGet free report

Lifesci Capital Reiterates Outperform Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)

Lifesci Capital Reiterates Outperform Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Bobakr azamianJosem trevejoHedge funds weigh in on tarsus pharmaceuticalsArtisan partners limited partnershipTarsus pharmaceuticals incTarsus pharmaceuticalsBlackrock incSecurities exchange commissionDeerfield management companylp seriesTarsus pharmaceuticals stock performanceNews ratings for tarsus pharmaceuticals dailyGoldman sachs groupGet free reportLifesci capitalExchange commissionPartners limited partnership

Bobak R Azamian Sells 40,000 Shares of Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Stock

Bobak R Azamian Sells 40,000 Shares of Tarsus Pharmaceuticals, Inc (NASDAQ:TARS) Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Bobakr azamianNews ratings for tarsus pharmaceuticals dailyQuarter for tarsus pharmaceuticalsTarsus pharmaceuticalsTarsus pharmaceuticals price performanceSecurities exchange commissionGoldman sachs groupVanguard group incTarsus pharmaceuticals company profileTudor investment corp et alDeutsche bankSei investments coTarsus pharmaceuticals incGet free reportExchange commissionSei investments

Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Up to $19 15

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $19.15, but opened at $19.64. Tarsus Pharmaceuticals shares last traded at $19.30, with a volume of 6,403 shares trading hands. Analyst Upgrades and Downgrades Several equities analysts recently commented on TARS […]

Diannec whitfieldBobakr azamianZurcher kantonalbank zurich cantonalbankInstitutional trading of tarsus pharmaceuticalsTarsus pharmaceuticals price performanceRoyal bankGoldman sachs groupTarsus pharmaceuticals company profileTarsus pharmaceuticals incTower research capitalSimplex tradingNews ratings for tarsus pharmaceuticals dailyTarsus pharmaceuticalsInsider activity at tarsus pharmaceuticalsGet free reportResearch capital

Tarsus Pharmaceuticals (TARS) Scheduled to Post Quarterly Earnings on Thursday

Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, November 9th. Analysts expect Tarsus Pharmaceuticals to post earnings of ($1.40) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link. Tarsus Pharmaceuticals (NASDAQ:TARS – Get […]

United statesBobakr azamianElizabeth yeu linWilliam blairGroup plcRoyal bankInstitutional investors weigh in on tarsus pharmaceuticalsTarsus pharmaceuticalsNews ratings for tarsus pharmaceuticals dailyTarsus pharmaceuticals incBarclays plcSecurities exchange commissionTarsus pharmaceuticals stock performanceEarnings history for tarsus pharmaceuticalsGet free reportExchange commission